Jump Financial LLC Increases Stock Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Jump Financial LLC lifted its stake in Mesa Laboratories, Inc. (NASDAQ:MLABFree Report) by 77.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,293 shares of the medical instruments supplier’s stock after buying an additional 1,437 shares during the period. Jump Financial LLC owned approximately 0.06% of Mesa Laboratories worth $346,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of MLAB. Citigroup Inc. lifted its stake in shares of Mesa Laboratories by 9.3% in the first quarter. Citigroup Inc. now owns 4,999 shares of the medical instruments supplier’s stock worth $1,275,000 after acquiring an additional 427 shares in the last quarter. MetLife Investment Management LLC raised its position in shares of Mesa Laboratories by 54.2% during the 1st quarter. MetLife Investment Management LLC now owns 2,668 shares of the medical instruments supplier’s stock worth $680,000 after purchasing an additional 938 shares during the period. Rhumbline Advisers grew its holdings in Mesa Laboratories by 0.7% in the 1st quarter. Rhumbline Advisers now owns 14,073 shares of the medical instruments supplier’s stock worth $3,587,000 after buying an additional 93 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in Mesa Laboratories by 14.5% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 4,523 shares of the medical instruments supplier’s stock worth $1,153,000 after buying an additional 574 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in Mesa Laboratories by 0.4% during the 1st quarter. BlackRock Inc. now owns 924,948 shares of the medical instruments supplier’s stock valued at $235,751,000 after purchasing an additional 4,061 shares in the last quarter. Institutional investors and hedge funds own 91.06% of the company’s stock.

Insider Buying and Selling at Mesa Laboratories

In related news, SVP Brian David Archbold sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $112.36, for a total transaction of $168,540.00. Following the completion of the transaction, the senior vice president now owns 558 shares in the company, valued at approximately $62,696.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 5.20% of the company’s stock.

Mesa Laboratories Trading Up 1.6 %

Shares of NASDAQ:MLAB opened at $95.33 on Tuesday. The company has a market cap of $513.83 million, a P/E ratio of 560.80 and a beta of 0.79. The stock’s 50-day moving average is $99.18 and its 200-day moving average is $107.57. Mesa Laboratories, Inc. has a 52-week low of $82.86 and a 52-week high of $187.75. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.86 and a current ratio of 2.68.

Mesa Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 15th. Shareholders of record on Thursday, February 29th will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date of this dividend is Wednesday, February 28th. Mesa Laboratories’s payout ratio is 376.49%.

Analyst Upgrades and Downgrades

Separately, Evercore ISI upgraded Mesa Laboratories from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $100.00 to $125.00 in a research report on Thursday, January 4th.

View Our Latest Research Report on MLAB

Mesa Laboratories Profile

(Free Report)

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.

Featured Articles

Institutional Ownership by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.